Type of white blood cell
POPULARITY
21 episodes with macrophages
9 episodes with macrophages
8 episodes with macrophages
9 episodes with macrophages
3 episodes with macrophages
6 episodes with macrophages
5 episodes with macrophages
3 episodes with macrophages
3 episodes with macrophages
In this episode, we detail the gut-immune axis, focusing on the protective mucus layer, antimicrobial peptides, and the role of lactoferrin in intestinal health. We discuss endogenous secretions and how lactoferrin functions as an antimicrobial, immunomodulatory, and iron-regulating glycoprotein, influencing microbial balance and intestinal barrier integrity. Additionally, we highlight lactoferrin testing and levels. We finish by going through supplementation as a phenomenal tool.Topics: 1. The Intestinal Barrier & Mucus Layer- The intestinal lumen, microbiome, mucus layer, epithelial cells, and lamina propria.- The mucus layer: antimicrobial peptides (AMPs) and secretory IgA (sIgA).- Intestinal epithelial cells including goblet cells and enterocytes.2. Immune Cells in the Gut- The lamina propria.- Macrophages, dendritic cells, neutrophils, B cells, T cells, mast cells, and more.3. Antimicrobial Peptides & Secretory IgA- AMPs and sIgA in the mucus layer regulate microbial balance and prevent pathogen adhesion.4. Lactoferrin: Functions & Sources- Iron-binding glycoprotein, antimicrobial and immunomodulatory properties.- Found in mucosal secretions, colostrum, and more.- Intestinal epithelial cells (IECs) and neutrophils.5. Lactoferrin's Role in Intestinal Health- Regulates iron absorption via lactoferrin receptors (LFR)on enterocytes.- Sequesters free iron, limiting bacterial growth, bacteriostatic.- Destabilizes bacterial membranes, cell lysis, bactericidal.6. Lactoferrin Levels- Neutrophils release lactoferrin during infection,increasing its presence in the large intestine.- Fecal lactoferrin levels.- Fecal calprotectin levels.7. Lactoferrin & Candida Overgrowth- Fungal membranes.- Aiding in the inhibition of biofilm formation.8. Lactoferrin Supplementation & Benefits- Supports gut microbiota, epithelial integrity, and immunemodulation.- Bovine colostrum and as a supplement.9. Conclusion- The intestinal mucus layer is key to gut barrier function.- Lactoferrin plays a central role in microbial regulationand immune defense.Thank you to our episode sponsors:1. Shop Fresh Press Farms'Peach Cider Vinegar at Sprouts locations nationwide, and check out their full collection here. 2. Shop CYLN's full skincare line here.Get Chloe's Book Today! "75 Gut-Healing Strategies & Biohacks" Follow Chloe on Instagram @synthesisofwellnessVisit synthesisofwellness.com
In this episode, we dive into the interplay between the gut microbiota (their postbiotics) and the immune system. We will examine how gut microbiome-derived metabolites, such as short-chain fatty acids (SCFAs) and polyphenol metabolites, influence immune function by modulating key cellular and molecular pathways within the intestinal mucosa. Additionally, we discuss strategies for supporting butyrate production and optimizing microbiome health to foster a balanced and resilient gut-immune axis. Topics: 1. Introduction Overview of the gut-immune axis. Importance of gut microbiome-derived metabolites in supporting immune function. 2. The Intestinal Barrier Layers of the intestinal wall Focus on mucosa, specifically the epithelium and lamina propria. 3. Structure of the Intestinal Layers The intestinal lumen, mucus layer, epithelium (with tight junctions), and lamina propria. Importance of the lamina propria as a hub for immune responses and structural integrity. 4. Cellular and Structural Components of the Lamina Propria Extracellular matrix (ECM): structural support. Fibroblasts and myofibroblasts. Lymphatic vessels: immune cell transport, linking mucosal and systemic immune systems. 5. Immune Cells in the Lamina Propria T cells: immune tolerance, regulatory T cells (Tregs). B cells: Secretory immunoglobulin A (sIgA). Dendritic cells: antigen sampling and presentation. Macrophages: pathogen clearance. Mast cells 6. Role of Secretory Immunoglobulin A (sIgA) Functions as a first-line defense in the intestinal mucus layer. Neutralizes pathogens, prevents epithelial adhesion. 7. Postbiotics Overview Bioactive compounds produced by gut microbiota. Examples: short-chain fatty acids (SCFAs) 8. Short-Chain Fatty Acids (SCFAs) and Their Functions Influence on Treg cells in the lamina propria, promoting immune tolerance. Butyrate also as an energy source for epithelial cells. 9. Supporting Butyrate Production Microbiome optimization to enhance beneficial butyrate-producing microbes. Use of prebiotics: resistant starch, soluble fibers, and polyphenols. Supplementation with sodium butyrate as an additional tool. 10. Other Postbiotics Antimicrobial peptides produced by beneficial microbes. Complex carbohydrates produced by beneficial microbes and can act as prebiotics. Polyphenol metabolites: Gut microbiota biotransforms polyphenols into bioactive metabolites with increased bioavailability. 11. Specific Polyphenols Examples: resveratrol, quercetin, and ellagitannins. Effects on intestinal barrier function, inflammation, and immune cell populations. "75 Gut-Healing Strategies & Biohacks" Follow Chloe on Instagram @synthesisofwellness Follow Chloe on TikTok @chloe_c_porter Visit synthesisofwellness.com --- Support this podcast: https://podcasters.spotify.com/pod/show/chloe-porter6/support
One of our MIB Agents OutSmarting Osteosarcoma 2024 grant recipients, Dr. Chris Richards, an Associate Professor from the University of Kentucky provides an overview of his funded work on macrophage engineered vesicles to treat pediatric osteosarcoma. This presentation focuses on the development of nanoscale vesicles derived from immune cells that can be utilized as immunomodulatory and therapeutic delivery platforms. Dr. Richards is a Professor in the Department of Chemistry at the University of Kentucky where he also serves as the Director of the Light Microscopy Facility and the Director of the Bioelectronics and Nanomedicine Center. His lab has developed novel nanoscale biomaterials for therapeutic delivery and in vivo sensing within the central nervous system. Incorporating these materials with nanofabricated devices has enabled his lab to develop new platforms for interrogating biological systems in cell culture, isolated tissue, and in vivo. Research in the Richards lab also focuses on the development of ensemble and single-molecule fluorescence spectroscopy techniques for the study of complex biological systems. His lab has recently applied this approach to study substance use disorders along with the development of therapeutic delivery platforms for cancer and spinal cord injury. Dr. Richards received his bachelor's degree in chemistry from the University of Maine and his PhD in physical chemistry from the Georgia Institute of Technology. He was also a postdoctoral researcher at Caltech where he was also a Beckman postdoctoral Scholar.
Immune explains how distinct olfactory mucosal macrophage populations mediate neuronal maintenance and pathogen defense, and failure to establish durable SARS-CoV-2-specific plasma cells in the bone marrow long-lived compartment after mRNA vaccination. Hosts: Vincent Racaniello, Cindy Leifer, Steph Langel, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server Nasal mucsosal macrophages, neuronal maintenance, and pathogen defense (Mucos Immunol) No long lived memory B cells after SARS-CoV-2 mRNA vaccination (Nat Comm) Time stamps by Jolene. Thanks! Music by Tatami. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv
TWiV notes the passing of virologist Diane Griffin, first H5N1 influenza virus in US pigs, Innate immune control of influenza virus interspecies adaptation via IFITM3, and antiviral trained innate immunity in alveolar macrophages after SARS-CoV-2 infection reduces secondary influenza A virus disease. Hosts: Vincent Racaniello, Alan Dove, Rich Condit, Kathy Spindler, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode MicrobeTV Discord Server MicrobeTV Fundraiser Diane Griffin passes (Johns Hopkins) Diane Griffin on TWiV 453 First H5N1 influenza virus in US pigs (CIDRAP) IFITM3 controls interspecies influenza virus infection (Nat Comm) Trained innate immunity by alveolar macrophages (Immunity) Timestamps by Jolene. Thanks! Weekly Picks Angela – See a giant ‘ghost particle' detector and more — October's best science images Brianne – October 27 APoD: Bat nebula Dickson – Nikon Small World Contest 2024 winners Kathy – AAAS 150th anniversary video, celebrating scientists and Pew's 2024 annual Trust in Science survey findings Rich – Cats Basically Are a Liquid After All, Study Confirms Alan – HHMI's Beautiful Biology site Vincent – EcoHealth Alliance Fights Back Listener Picks Hunter – Don't stop me now: Queen's Brian May on saving badgers — and the scientific method Anne – Reasons to be cheerful Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.
In this episode, we're joined by Noam Baumatz, CEO and Co-Founder of Noga Therapeutics, a company dedicated to developing gene therapies for rare and severe diseases through engineering macrophages. Motivated by his highly personal experience of rare disease, Noam founded Noga to develop the type of gene therapies his daughter was unable to access. He and Patrick discuss his work with parents and families affected by rare disease, the road to effective, financially accessible gene therapies, and Noam's previous work in traditional Chinese medicine.
1er épisode / 5, de la série sur le purpura thrombopénique immunologique (PTI). Episode 1 : Maladie rare - Qu'appelle-t-on PTI ? Invité : Pr Bertrand Godeau, médecin interniste, praticien hospitalier au sein du service de médecine interne de l'hôpital Henri Mondor à Créteil, coordinateur de l'actualisation du PNDS sur le PTI de l'adulte, médecin coordonnateur du centre de référence CeReCAI, affilié à la filière MaRIH. https://www.aphp.fr/service/service-54-026 https://marih.fr/groupe-experts/cerecai-centre-de-reference-des-cytopenies-auto-immunes-de-ladulte/ 1️⃣ Qu'appelle-t-on purpura thrombopénique immunologique (PTI) ? [0'37 – 1'56] ✔️ Maladie auto-immune, avec production d'anticorps anti-plaquettes et leurs précurseurs (mégacaryocytes), ✔️ Maladie rare mais responsable de 4000 hospitalisations par an. ✔️ Sujets touchés de tout âge. Age moyen de diagnostic 50 ans. Pour plus d'informations, retrouvez notre page article : https://rarealecoute.com/le-purpura-thrombopenique-immunologique-pti/ 2️⃣ Quel est le tableau clinique rencontré chez les patients touchés par un PTI ? [1'57 – 3'37] ✔️ Risque de saignements : cutanées, des muqueuses (gencives, nez), ✔️ Les saignements graves sont rares (
BUFFALO, NY- October 24, 2024 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 19 on October 3, 2024, entitled “A new model and precious tool to study molecular mechanisms of macrophage aging.” As highlighted in the abstract, the accumulation of senescent cells, marked by a senescence-associated secretory phenotype (SASP), plays a role in chronic inflammation and age-related diseases (ARD). During aging, macrophages can develop a senescent-like phenotype with altered functions, promoting the buildup of senescent cells. In the context of aging and ARD, controlling the resolution of inflammation and preventing chronic inflammation—particularly by targeting macrophages—should be a priority. In their paper, researchers Rémy Smith, Kévin Bassand, Ashok Dussol, Christophe Piesse, Eric Duplus, and Khadija El Hadri from Sorbonne Université in Paris and Université Sorbonne Paris Nord in Bobigny, France, developed an in vitro model of murine peritoneal macrophage aging. Using this model, they demonstrated that chronic treatment with CB3, a thioredoxin-1 mimetic anti-inflammatory peptide, completely prevents the increase of p21CIP1 and allows day 14 macrophages to maintain their proliferative activity. "We describe a new model of macrophage aging with a senescence-like phenotype associated with inflammatory, metabolic and functional perturbations.” DOI - https://doi.org/10.18632/aging.206124 Corresponding authors - Eric Duplus - eric.duplus@sorbonne-universite.fr, and Khadija El Hadri - khadija.zegouagh@sorbonne-universite.fr Video short - https://www.youtube.com/watch?v=LfN78LR-CYU Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206124 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, macrophage, inflammation, senescence, thioredoxin-1 mimetic peptide About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
Mark helps Grant recap a national travesty, but only in a fair and measured way. NBC shouldn't expunge important historical records.Mark brings Ollie and Quentin. Don't listen to Grant: that's the actual name. POV cameras on professional athletes would be cool for a certain kind of sports nerd.Grant brings Brewster Rockit. This episode description is authoritatively not brought to you by autocorrect.Send feedback to comicalstart@gmail.com.
Dr. Peter Moore chats with Dr. Marilia Zuttion on her article, "Interstitial Macrophages Mediate Efferocytosis of Alveolar Epithelium during Influenza Infection."
On this episode of JHLT: The Podcast, the JHLT Digital Media Editors explore two studies from the July issue of The Journal of Heart and Lung Transplantation. Digital Media Editor Marty Tam, MD, a transplant cardiologist from the University of Michigan in Ann Arbor, hosts this episode. First, Dr. Tam and Digital Media Editor Erika Lease, MD, FCCP, interview their first guest, Daniel Calabrese, MD, first author on the study “Macrophage and CD8 T cell discordance are associated with acute lung allograft dysfunction progression.” The study's authors sought to tackle challenges behind early detection of chronic lung allograft dysfunction (CLAD) by identifying biomarkers associated with acute lung allograft dysfunction (ALAD) progression to CLAD. To do this, they collected bronchoalveolar lavage (BAL) cells at the time of ALAD diagnosis and performed single cell RNA sequencing to identify significant differences in 26 unique cell populations across groups, with discordant CD8 T cells and macrophages providing the best discrimination between ALAD with decline from ALAD with recovery and controls. Dr. Calabrese discusses how his team identified the diagnostic criteria, why the biomarkers might lead ALAD to progress to CLAD, and how the findings might lead to early targeted therapies. Next, Dr. Tam joins and Digital Media Editor Khue Ton, MD and David Schibilsky, MD, to interview their next guest, David D'Alessandro, MD, the Surgical Director of Cardiac Transplantation and MCS at Massachusetts General Hospital in Boston. Dr. D'Alessandro was the first author on the study “Impact of controlled hypothermic preservation on outcomes following heart transplantation,” which sought to assess the impact of the Paragonix SherpaPak Cardiac Transport System, a device allowing controlled hypothermic preservation, on rates of primary graft dysfunction (PGD) and post-transplant mortality. The key finding was that controlled hypothermic preservation was associated with a lower incidence of severe PGD – 6.6% compared to ice storage at 10.4%. In the conversation, Dr. D'Alessandro answers questions about the need for innovation over traditional ice cold storage, the greatest advantages of controlled hypothermic approaches, and the next steps in this research. Follow along at www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.
Oxygen is activated quantum-mechanically in the body to act against bacterial infections. Professor Robert C Allen shows that the antibacterial action of oxygen can be monitored by measuring the light emitted as the immune system responds to pathogen attacks. He has developed techniques based on the use of chemiluminigenicmolecules which provide unprecedented insight into the neutrophil activity and afford powerful point of care diagnostic tools for immune system monitoring. Read more in Research Features: doi.org/10.26904/RF-151-6124846326Read the original research: doi.org/10.3390/antiox11030518
The key to understanding oxygen activation is the conversion of this molecule into a reactive singlet species within neutrophil cells in the blood. This process leads to light emission, which can be used to monitor in real time how the immune system functions.Based on over 40 years of research, Professor Robert C Allen proposes an exquisitely detailed model of how oxygen becomes an aggressive bactericidal agent in the body. Read more in Research Features: doi.org/10.26904/RF-151-6036339265Read the original research: www.intechopen.com/chapters/64123
Robert Towarnicki, CEO and Co-founder of SIRPant Immunotherapeutics, discusses cancer-specific immunotherapy for aggressive tumors, the role macrophages play in the immune response to cancer, and how cancer cells can shut down this response. SIRPant Immunotherapeutics aims to modify macrophages by reducing SIRPα expression, triggering them to eat cancer cells and educate other immune cells. Early evidence demonstrates potential effectiveness for various cancers, including non-Hodgkin's lymphoma and solid tumors. Robert emphasizes this therapy's scalability and cost advantages compared to other cell therapies like CAR-T. He also highlights the potential for treating rare diseases and the ability of SIRPant-M to target a wide range of cancers without the need for pre-identified targets. Robert explains, "Macrophages are a normal immune cell type in your body. They normally function to recognize foreign invaders and process them in the sense of phagocytizing or eating the foreign protein and invader, if it's a virus, a bacteria, or a cancer. Unfortunately, cancers are very good at shutting down this immune response. So, we need to modify the macrophage and re-empower it to elicit the other immune cells in the body to do their job and eliminate cancer." "I think one of the mistakes we've seen with others working with the macrophage in this situation was the lack of appreciation for the role of SIRPα. Our inventor, Dr. Yuan Liu at Georgia State University, identified this early on through a knockout mouse, a mouse where SIRPα was genetically removed from it. With that mouse, she could discover and learn how macrophages function and react. It directed us to the whole concept of removing SIRPα from the macrophage. Now, removal alone is not enough. You also have to activate a macrophage. So, a macrophage exists in multiple states. There's an active state, and then there's an inactive state." #SIRPant #Immunotherapy #Macrophages #Oncology #Cancer sirpantimmunotx.com Download the transcript here
Robert Towarnicki, CEO and Co-founder of SIRPant Immunotherapeutics, discusses cancer-specific immunotherapy for aggressive tumors, the role macrophages play in the immune response to cancer, and how cancer cells can shut down this response. SIRPant Immunotherapeutics aims to modify macrophages by reducing SIRPα expression, triggering them to eat cancer cells and educate other immune cells. Early evidence demonstrates potential effectiveness for various cancers, including non-Hodgkin's lymphoma and solid tumors. Robert emphasizes this therapy's scalability and cost advantages compared to other cell therapies like CAR-T. He also highlights the potential for treating rare diseases and the ability of SIRPant-M to target a wide range of cancers without the need for pre-identified targets. Robert explains, "Macrophages are a normal immune cell type in your body. They normally function to recognize foreign invaders and process them in the sense of phagocytizing or eating the foreign protein and invader, if it's a virus, a bacteria, or a cancer. Unfortunately, cancers are very good at shutting down this immune response. So, we need to modify the macrophage and re-empower it to elicit the other immune cells in the body to do their job and eliminate cancer." "I think one of the mistakes we've seen with others working with the macrophage in this situation was the lack of appreciation for the role of SIRPα. Our inventor, Dr. Yuan Liu at Georgia State University, identified this early on through a knockout mouse, a mouse where SIRPα was genetically removed from it. With that mouse, she could discover and learn how macrophages function and react. It directed us to the whole concept of removing SIRPα from the macrophage. Now, removal alone is not enough. You also have to activate a macrophage. So, a macrophage exists in multiple states. There's an active state, and then there's an inactive state." #SIRPant #Immunotherapy #Macrophages #Oncology #Cancer sirpantimmunotx.com Listen to the podcast here
Uveitis is a heterogenous group of inflammatory eye diseases for which current cytokine-targeted immune therapies are effective for only a subset of patients. Dr. Edmund Tsui is joined by Dr. Lynn M. Hassman and MD/PhD student Joseph B. Lin to explore potential common underlying mechanisms that exist for immune cell recruitment in uveitis in their Ophthalmology Science article, “Aqueous macrophages contribute to conserved CCL2 and CXCL10 gradients in uveitis” Aqueous Macrophages Contribute to Conserved CCL2 and CXCL10 Gradients in Uveitis. Lin, Joseph B. et al. Ophthalmology Science, Volume 4, Issue 4. The Ophthalmology-family of journals is now on Instagram. Follow aaojournal for clinical images, research articles, news, editorials, podcasts, and more! Sign up for the next Ophthalmology Journal Virtual Club on June 19, 2024, at https://store.aao.org/ophthalmology-virtual-journal-club.html
In this episode of The Metabolic Classroom, Dr. Ben Bikman challenges the traditional view that saturated fats are the primary cause of atherosclerotic plaques and heart disease. He asserts that while plaques, or atheromas, in coronary arteries are composed partly of fats and foam cells, the exact process of plaque formation remains speculative. Dr. Bikman emphasizes that anyone claiming to know the definitive cause of plaque formation is likely overstating their knowledge. Foam cells, which are fat-laden macrophages, play a critical role in plaque development and are consistently present at the sites of these plaques.Dr. Bikman explains that inflammation is a significant factor in atherosclerosis, and C-reactive protein (CRP), a marker of inflammation, is a better predictor of heart disease than LDL cholesterol. He describes how macrophages engulf oxidized LDL cholesterol, turning into foam cells and secreting pro-inflammatory proteins like CRP. This process is driven by the presence of oxidized lipids, particularly those derived from omega-6 polyunsaturated fats such as linoleic acid, which are prevalent in modern diets due to the widespread use of vegetable oils.Ben highlights several studies to support his argument. A notable study from 1979 by Brown and Goldstein showed that macrophages only consume LDL cholesterol when it is oxidized, not in its native form. Another study from 1998 found that oxidized LDL containing specific bioactive lipids, nine and 13 HODE, is particularly problematic. These oxidized lipids are derived from linoleic acid, not from saturated or monounsaturated fats. Moreover, historical dietary studies, such as the Minnesota Coronary Experiment and the Sydney Diet Heart Study, revealed that participants consuming more polyunsaturated fats had higher mortality rates than those consuming saturated fats.To conclude, Dr. Bikman argues that the traditional belief that saturated fat causes heart disease is flawed. He points out that recent studies, including a correlational study published in the British Medical Journal, show that refined grains, not saturated fats, are more strongly linked to heart disease and overall mortality. He suggests that the real dietary culprit is the overconsumption of omega-6 polyunsaturated fats, particularly linoleic acid, found in processed foods. This shift in perspective underscores the importance of reevaluating dietary guidelines and focusing on the types of fats consumed.#HeartHealth #SaturatedFat #Atherosclerosis #Inflammation #InsulinResistance #LDLCholesterol #OxidizedLDL #FoamCells #Macrophages #BenBikman #MetabolicHealth #CholesterolMyths #LinoleicAcid #PolyunsaturatedFats #DietaryFats #CardiovascularResearchStudies referenced:Binding Site on Macrophages that Mediates Uptake in Degradation by Brown and Goldstein (1979): https://academic.oup.com/clinchem/article/46/6/829/5641219 Oxidized LDL Regulates Macrophage Gene Expression (1998): You can find more details on this study in resources like ScienceDirect and Cell Journal (you may need specific access or subscriptions to retrieve full texts).Strong Increase in Hydroxy Fatty Acids Derived from Linoleic Acid in Human Low-Density Lipoproteins of Atherosclerotic Patients (1998): https://www.sciencegate.app/document/10.1016/s0009-3084(97)00095-9 Learn more: https://www.insuliniq.com Hosted on Acast. See acast.com/privacy for more information.
Episode #311. Some people follow a ketogenic diet seeking to lose weight, feel more energised, or gain control over their eating habits. Others may turn to this diet in an effort to treat their epilepsy, bipolar disorder, or diabetes. Regardless of their reasoning for adopting this eating pattern, a key question remains: can high LDL cholesterol levels on a ketogenic diet be safe? Today I sit down with Dr William Cromwell, MD and Dave Feldman to explore this question. In this discussion, Dr William Cromwell and Dave Feldman share their professional opinions on whether high cholesterol on a keto diet is a problem. We investigate where their opinions align and where they differ, where Dave's hypotheses diverge from the norm, and what we do and don't know with the available evidence. We also explore the significance of ApoB, lifespan and healthspan considerations, research Dave is currently conducting, and much more. Specifically, we discuss: Intro (00:00) Dr. William Cromwell: Background as a Lipidologist and LDL Research (01:54) Dave Feldman's Ketogenic Diet and Elevated LDL Experience (05:34) Unpacking the Lipid Hypothesis and Cardiovascular Risk (12:30) The history and evolution of the lipid hypothesis (20:40) The role of apoB lipoproteins in atherosclerosis (23:39) Factors beyond apoB involved in atherosclerosis and mortality risk (31:59) The complexity of interpreting mortality data in the context of apoB (41:40) Macrophages and the process of atherosclerosis (44:00) Beyond ApoB: Metabolic Vulnerability, Inflammation and Mortality Risk (52:57) Transcytosis: A New Perspective on LDL Movement and Atherosclerosis (1:10:36) Exploring Low Cholesterol Impacts and Genetic Disorders (1:17:30) Macrophage function and phenotype in the context of different drivers of high apoB (1:22:30) Defining Lean Mass Hyper-responders in the Context of a Ketogenic Diet (1:31:40) Investigating PCSK9 and Its Effects on Healthspan (1:38:00) Assessing cardiovascular risk in lean mass hyper-responders (1:43:50) Statin safety, adverse effects, and patient reluctance (2:01:54) Ketogenic Diets and Elevated LDL: Balancing Individual Risks and Benefits in the Absence of Long-term Data (2:10:40) Insulin Resistance, ApoB, and Cardiovascular Risk: Navigating the Challenges in Assessment and Imaging (2:18:12) Lean Mass Hyper-responder Study: Design, Recruitment, and Eligibility Criteria (2:32:45) Closing Perspectives on Research and Dietary Options (3:04:47) Outro (3:06:42) Connect with Dr William Cromwell on Twitter/X, LinkedIn, and his website, https://www.mylipid.com/. Discover more of his work with Precision Health Reports on Twitter/X, LinkedIn, Facebook, Instagram, and at https://precisionhealthreports.com/. Connect with Dave Feldman on Twitter/X, YouTube, and Instagram, and discover more of his work at https://citizensciencefoundation.org/, https://ownyourlabs.com/, and https://cholesterolcode.com/. This episode is brought to you by: InsideTracker If you want to improve your health, you need to measure where you're currently at. InsideTracker analyses up to 48 blood biomarkers including ApoB, LDL, HDL, A1C, and more before giving you advice to optimise your health. Get a 20% discount on your first order at insidetracker.com/simon. Shopify Shopify, the world's leading e-commerce platform, helps you turn browsers into buyers with the internet's best-converting check out–up to 36% better compared to other leading e-commerce platforms. To boost your conversion rate, and grow your business, sign up for a one-dollar-per-month trial period at shopify.com/proof. Sun Home Saunas Invest in your body and mind with Sun Home Saunas, pioneers in crafting premium saunas and cold plunges. Safe, effective, research-backed wellness tools to improve cardiovascular health, offer psychological benefits, and reduce muscle soreness. Head to sunhomesaunas.com/theproof for $300 off your purchase.
References Int J Mol Sci. 2019 Oct; 20(20): 5028. Lennon-McCartney. 1964. "Ill Be Back" https://youtu.be/fJSTBNTac6k?si=rr4rWE86TIs8EZcL Bruch, M. 1866. Violin Concerto 1. G minor https://youtu.be/9BeV9XDs64w?si=AvEAQch7T8TJrt05 --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support
TWiV reviews measles outbreaks in England and Europe, 2 fatal Nipah virus cases in Bangladesh, yellow fever outbreak in Sudan, and discuss how the type of immunodeficiency influences the outcome of SARS-CoV-2 infection, and programming of alveolar macrophages by intestinal bacteria that influences severity of respiratory viral infection. Hosts: Vincent Racaniello, Dickson Despommier, and Rich Condit Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode MicrobeTV Discord Server MicrobeTV store at Cafepress Become a member of ASV (asv.org) Research assistant position in Rosenfeld Lab CBER/FDA (pdf) The New City by Dickson Despommier Viruses of Microbes 2024 Pig virus imperils food security in Borneo (Science) Measles outbreaks in UK and Europe (Nature) Fatal Nipah virus infections in Bangladesh (CIDRAP) Yellow fever outbreak in Sudan (Crisis24) COVID-19 influenced by type of immunodeficiency (Sci Transl Med) Intestinal microbiota programming of alveolar macrophages (Cell Host Microbe) Letters read on TWiV 1085 Timestamps by Jolene. Thanks! Weekly Picks Dickson – JWST details of 19 spiral galactic centers Rich – Great White Shark Attack And Breach Vincent – Black History Month and Lost Photographs of Black America Listener Picks Louise – The Mystery Of The Village That Beat The Black Death Pierre – Three things airlines don't want you to know Brandon – Professor Dave explains Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv
In this amazing study, Dutch researchers used muscle biopsies in long COVID patients suffering from post-exertional malaise. They found that the muscle phenotype had changed, resulting in lower exercise capacity. They also found mitochondrial function issues and local amyloid accumulation. Macrophages and CD3+ T cells were also infiltrated in the muscle tissues. The clinical takeaways are to keep inflammation under control, utilize light exercises and not stressful ones, and optimize mitochondrial health. Let's review. DrBeen: Medical Education Online https://www.drbeen.com/ FLCCC | Front Line COVID-19 Critical Care Alliance https://covid19criticalcare.com/ References (Jan. 11, 2024) Muscle abnormalities worsen after post-exertional malaise in long COVID - Nature Communications https://www.nature.com/articles/s41467-023-44432-3 A discovery in the muscles of long COVID patients may explain exercise troubles https://www.npr.org/sections/health-shots/2024/01/09/1223077307/long-covid-exercise-post-exertional-malaise-mitochondria Disclaimer: This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only. Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional.
Juliet Morrison joins Immune to discuss her career and the research of her laboratory showing that pleural macrophages translocate to the lung during infection to promote improved influenza outcomes. Hosts: Vincent Racaniello, Steph Langel, Cynthia Leifer, and Brianne Barker Guest: Juliet Morrison Click arrow to play Download Immune 76 (48 MB .mp3, 67 min) Subscribe (free): Apple Podcasts, Google Podcasts. RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server Publishing is broken (Solving for Science) Pleural macrophages move to the lung during influenza (PNAS) Time stamps by Jolene. Thanks! Music by Steve Neal Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv
References Immunohorizons. 2022 Jun 22; 6(6):366–372. Biochem J. 2009 Dec 14;425(1):265-74 Chem Rev. 2011 Oct 12; 111(10): 6321–6340. Telemann, Georg Philipp. 1699.Trauer-Actus, Cantus Cölln, Junghänel https://youtu.be/0yS7YIcwBq0?si=UaVMZzBtZc27t5Xp --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support
I would like to share information about a paper authored by a team of researchers from Germany, Finland, and Switzerland, with Gunther Felmerer leading the group.The paper, titled "Increased levels of VEGF‑C and macrophage infiltration in lipedema patients without changes in lymphatic vascular morphology," was published in the peer-reviewed journal Scientific Reports in July 2020.The study aimed to investigate and characterize the tissue and lymphatic vascular aspects of lipedema. This research contributes another valuable piece to the understanding of lipedema.
This is an accredited continuing education series of two (2) podcasts as downloadable audio files (MP3). In this podcast series, Dr. Scott Canna and Dr. Alexei Grom discuss diverse mechanisms and clinical presentations in patients with suspected MAS, approaches for the timely diagnosis of MAS, and considerations for appropriate treatment and management strategies. Launch Date: December 21, 2023 Release Date: December 21, 2023 Expiration Date: November 30, 2024 FACULTY BIOSScott Canna, MDAssistant Professor of PediatricsUniversity of Pennsylvania Perelman School of MedicineAttending Physician, Rheumatology and Immune DysregulationThe Children's Hospital of PhiladelphiaPhiladelphia, Pennsylvania Alexei Grom, MDProfessor of PediatricsResearch DirectorDivision of RheumatologyCincinnati Children's Hospital Medical CenterCincinnati, Ohio This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/expert-insights-on-mas-sjiaaosd-and-macrophage-activation-syndrome-an-interactive-case-based-discussion-37
This is an accredited continuing education series of two (2) podcasts as downloadable audio files (MP3). In this podcast series, Dr. Scott Canna and Dr. Alexei Grom discuss diverse mechanisms and clinical presentations in patients with suspected MAS, approaches for the timely diagnosis of MAS, and considerations for appropriate treatment and management strategies. Launch Date: December 21, 2023 Release Date: December 21, 2023 Expiration Date: November 30, 2024 FACULTY BIOSScott Canna, MDAssistant Professor of PediatricsUniversity of Pennsylvania Perelman School of MedicineAttending Physician, Rheumatology and Immune DysregulationThe Children's Hospital of PhiladelphiaPhiladelphia, Pennsylvania Alexei Grom, MDProfessor of PediatricsResearch DirectorDivision of RheumatologyCincinnati Children's Hospital Medical CenterCincinnati, Ohio This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/expert-insights-on-mas-sjiaaosd-and-macrophage-activation-syndrome-an-interactive-case-based-discussion-37
Carla Kim, Ph.D., explains how aging impacts lung cell biology and its potential to reshape our understanding of diseases, including lung cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39254]
Carla Kim, Ph.D., explains how aging impacts lung cell biology and its potential to reshape our understanding of diseases, including lung cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39254]
Carla Kim, Ph.D., explains how aging impacts lung cell biology and its potential to reshape our understanding of diseases, including lung cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39254]
Carla Kim, Ph.D., explains how aging impacts lung cell biology and its potential to reshape our understanding of diseases, including lung cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39254]
Carla Kim, Ph.D., explains how aging impacts lung cell biology and its potential to reshape our understanding of diseases, including lung cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39254]
Immune reveals the total mass (1.2kg), number (1.8 trillion), and distribution of immune cells in the human body, with macrophages contributing nearly 50% of the total cellular mass. Hosts: Vincent Racaniello, Cynthia Leifer, and Brianne Barker Subscribe (free): Apple Podcasts, Google Podcasts. RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server Immune cells in the human body (PNAS) Letters read on Immune 73 Time stamps by Jolene. Thanks! Music by Steve Neal. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv
Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]
Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]
Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]
Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]
Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]
References Telemann Georg P. 1765. Overture D Major, TWV 55:D18 | Tafelmusik https://youtu.be/8r-IFLtN9x4?si=T2hp65oGT--dTivY Leukemia 2020 volume 34, pages 75–86 Nat Cell Biol. 2019 Mar; 21(3): 397–407 --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support
References Saint-Saens. C. 1886. Symphony 3 (avec orgue) OP.78 J Clin Invest. 2011 Dec 1; 121(12):4903–4915 Cell Metab. 2022 Dec 6; 34(12): 2036–2046.e8. --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support
References Luigi Boccherini: Symphony Op. 12 No. 4 in D Minor JCI Insight. 2016 Nov 17; 1(19): e87748 Front Immunol. 2023; 14: 1149366 Adv Biol Regul.2019 Jan;71:41-54. Int. J. Mol. Sci. 2019, 20(6), 1505 --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support
References Cells. 2022 Mar; 11(6): 997. Nat Cell Biol. 2019 Mar; 21(3): 397–407. Rheumatology (Oxford). 2023 Jul; 62(7):2611–2620 --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support
Immune explains how, in a mouse model of roundworm infection with Nippostrongylus brasiliensis, exposure to lung-migrating helminths protects mice against SARS-CoV-2 infection. Hosts: Cynthia Leifer, Stephanie Langel, and Brianne Barker Subscribe (free): Apple Podcasts, Google Podcasts. RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server Helminth protects against murine SARS-CoV-2 infection (Sci Immunol) Pandemic spared Africa (ScienceInsider) Letters read on Immune 71 Time stamps by Jolene. Thanks! Music by Steve Neal. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv
References Rheumatology (Oxford). 2023 Jul; 62(7):2611–2620 Science Immunology.2018.26 Jan Vol 3, Issue 1. Nature. 2020 Jun; 582(7813): 577–581. --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support
In this flash briefing, Ivor Cummins delves into the role of macrophages and the initial manifestations of unhealthy adipose tissue.
Learn about the role of macrophages in atherosclerosis. Where do they really come from? How do they contribute to the plaque? How are they driving the immune reaction? What's the relation between macrophages and T cells? We'll also look at vascular inflammation in the form of autoimmune vasculitis and note the similarities with atherosclerosis.#LDL #atherosclerosis #choelsterol #plaque #heartdisease #vasculitis #macrophagesMy website: vyvyanelohmd.comCheck out the livestream datesWork with me to improve your metabolic health (Metabolic Foundations Program): www.tulaversitycampus.comif you are a health coach or clinician and want to acquire a solid foundation in metabolic health based on the most current science: www.tulaversitycampus.com
A fascinating new look at treating periodontal disease using macrophages differently. Katrina Sanders, RDH takes a look at work coming from Kings College in London related to using telocytes as a regulator of M1 vs M2 macrophages! Resources: More Fast Facts: https://www.ataleoftwohygienists.com/fast-facts/ Katrina Sanders Website: https://www.katrinasanders.com Katrina Sanders Instagram: https://www.instagram.com/thedentalwinegenist/ Jing Zhao, Anahid A Birjandi, Mohi Ahmed, Yushi Redhead, Jose Villagomez Olea, Paul Sharpe (2022). Telocytes regulate macrophages in periodontal disease. Published in eLife https://doi.org/10.7554/eLife.72128
A new editorial paper was published in Oncotarget's Volume 14 on June 6, 2023, entitled, “A macrophage is a macrophage is a macrophage—in metastasis.” In this new editorial, researcher Thomas T. Tapmeier from Monash University, Hudson Institute of Medical Research and University of Oxford discusses a recent study he co-authored on how lung macrophages evolve during metastatic growth of lung colonies in a mouse model of melanoma. Macrophages have important roles in the response to infection or injury and can orchestrate the appropriate response after sampling their microenvironment, devouring anything untoward and presenting ingested antigens to T cells to elicit an adaptive immune response. In adult life, they develop from bone marrow-derived precursors and circulating monocytes, which differentiate into macrophages within tissue. “Apart from their role in clearing challenges to tissue integrity, macrophages have an essential role in growth-related processes such as angiogenesis and vascular remodelling, neural patterning, and ductal growth of developing glands [2].” However, their powers can be usurped by tumors, which cannot grow beyond a certain size or metastasis without the help of macrophages. This is crucial, as the primary tumor might be amenable to treatment—so that patients can live with it—but metastasis is yet untreatable and inevitably becomes incompatible with survival. Macrophages perform a range of physiological functions and are able to activate function-specific gene repertoires; however, surface markers for selectively targeting macrophages of one or another function are still elusive, despite recent advances in the field. “Thus, therapy attempts based on countering macrophages try to target the surface receptors that recruit them to sites of infection, inflammation or growth [5].” DOI - https://doi.org/10.18632/oncotarget.28423 Correspondence to - Thomas T. Tapmeier - thomas.tapmeier@monash.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28423 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, metastasis, macrophages, melanoma, CCR About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
Host Jeremy C. Park talks with Amy Thomas, Diversity, Equity and Inclusion Program Manager, Customer Satisfaction with AutoZone and Team Captain for the AutoZone Striders, along with Elizabeth Ennis, Senior Development Manager with the American Cancer Society, who both celebrate the AutoZone Striders being recently honored as the top national fundraiser for Making Strides Against Breast Cancer (MSABC), raising $202,222 for breast cancer research. In addition, the team was able to name an existing post-doctoral fellowship research grant in honor of their team. Named to honor all AutoZoners and their families touched by cancer, the AutoZone Breast Cancer Research Grant was awarded to Baylor College of Medicine in Houston, Texas. The project is led by researcher Diego A. Pedroza, PHD, and is titled Treatment of Breast Cancer Metastasis by Therapeutic Manipulation of Macrophages with Combined Chemotherapy. The grant will be active until 2025.During the interview, Elizabeth talks about the American Cancer Society and their national and local efforts and impact. Amy talks about her personal passion for supporting the American Cancer Society with her mother, and how supporting the organization helps strengthen AutoZone's team culture and commitment to making an impact in the community. Both share encouragement for how other companies can get involved and support the effort.Visit www.cancer.org to learn more about the American Cancer Society and www.AutoZone.com to learn more about AutoZone.
This week we've invited Dr. Lauren Henderson of Boston Children's Hospital to discuss what Macrophage Activation Syndrome (MAS) is, how to diagnose it and which medications are used to treat it. Dr. Henderson also explains her efforts to partner with healthcare professionals in other fields (who may use a different name for MAS) seeking to understand what treatments they use when confronted with MAS and to establish a formalized process in evaluating and treating these patients together.
KSQD 5-31-2023: Stress raises glucocorticoids and inflammation in the gut, thus causing irritable bowel syndrome; Mosquitos are attracted to terpenes in many soaps, but repelled by those with coconut oil; Editorial about gender selection and the altering of sexual development
© 2020-2025 Ivy Podcast Discovery LLC
